Fig. 9: GA and MgIG attenuate Crizotinib-induced hepatocyte ferroptosis via the Stat1/Nrf2 pathway in vivo. | Cell Death & Disease

Fig. 9: GA and MgIG attenuate Crizotinib-induced hepatocyte ferroptosis via the Stat1/Nrf2 pathway in vivo.

From: The involvement of the Stat1/Nrf2 pathway in exacerbating Crizotinib-induced liver injury: implications for ferroptosis

Fig. 9: GA and MgIG attenuate Crizotinib-induced hepatocyte ferroptosis via the Stat1/Nrf2 pathway in vivo.

A and B the cell viability of HL7702 and AML12 cells treated with 13 μM Crizotinib and/or GA (n = 3) or MgIG (n = 6) at different concentrations for 48 h. C57 male mice were treated with 120 mg/kg/day Crizotinib and/or 5 mg/kg/day GA or 10 mg/kg/day MgIG for 3 weeks. C and D The levels of serum ALT (C) and AST (D) were analyzed (n = 8). E Representative images of H&E staining in liver tissues (×20). F The protein levels of pStat1 Ser727, Stat1, total Nrf2, SLC7A11, and GPX4 of liver lysate were analyzed by western blot (n = 6). G The mRNA levels of Nrf2, GCLC, GCLM, GPX4, FPN, and FTH1 of liver lysate were analyzed by RT-qPCR (n = 8). H, J Cys, GSH, the reduced GSH/HSSG (H, n = 8), MDA, and LPO (J, n = 8) were measured by reagent kit. I Total Iron concentration was measured by reagent box and ICP-MS (n = 8). K Representative pictures of 4-HNE expression in each group measured by immunohistochemical staining (×20). *P < 0.05, **P < 0.01 and ***P < 0.001 vs. the control group. #P < 0.05, ##P < 0.01 and ###P < 0.001 vs. Crizotinib group.

Back to article page